Molecular Pharmacodynamics-Guided Scheduling of Biologically Effective Doses: A Drug Development Paradigm Applied to MET Tyrosine Kinase Inhibitors-Reference-Cited by-同舟云学术

Molecular Pharmacodynamics-Guided Scheduling of Biologically Effective Doses: A Drug Development Paradigm Applied to MET Tyrosine Kinase Inhibitors

Published:2018-02-14 Issue:3 Volume:17 Page:698-709
ISSN:1535-7163
Container-title:Molecular Cancer Therapeutics
language:en
Short-container-title:Mol Cancer Ther

Author:

Srivastava Apurva K.,Hollingshead Melinda G.,Govindharajulu Jeevan Prasaad,Covey Joseph M.,Liston Dane,Simpson Melanie A.,Peggins James O.,Bottaro Donald P.,Wright John J.,Kinders Robert J.,Doroshow James H.,Parchment Ralph E.

Funder

National Cancer InstituteNIHNIH

SRI

Southern Research Institute

University of California, San Francisco

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular biology of targeting lymphangiogenesis in cancer: Therapeutic strategies and future promise;Fundamental Research;2024-04

2. The Preclinical Pharmacology of Tepotinib—A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations;Molecular Cancer Therapeutics;2023-03-30

3. Differences in Sustained Cellular Effects of MET inhibitors Are Driven by Prolonged Target Engagement and Lysosomal Retention;Molecular Pharmacology;2022-11-18

4. Translational pharmacokinetic‐pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose;CPT: Pharmacometrics & Systems Pharmacology;2021-05

5. Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors;Clinical Cancer Research;2021-04-16